#neoadjuvant search results
💡Assessing #pathological response to #neoadjuvant therapy in #renal cell carcinoma: a systematic review and #guidelines for sampling and reporting standards from the International Neoadjuvant Kidney Cancer Consortium thelancet.com/journals/lanon… @TheLancetOncol It is a true honor…
END OF YEAR TOP ALL CANCER TRIALS in 2024! JUST in on 1 JAN 2025: Paper 1: #neoadjuvant checkpoint inhibitor Phase 3 trial in melanoma! #NADINA trial shows ipi+nivo significantly improves EFS vs. adjuvant nivo alone (HR 0.32, p<0.0001). #ASCO24 plenary #Melanoma @ASCO…
I am so proud of leading the #Neoadjuvant NADINA phase 3 clinical trial (with Dutch colleague Prof Blank from @NKI_nl) and with the support of my amazing colleagues at @MelanomaAus. Today, this #immunotherapy regimen (ipilimumab+nivolumab) is listed on PBS for ALL AUSSIES with…
Please join me and other @MelanomaAus multidisciplinary experts at our specialist hybrid #symposium on Neoadjuvant Treatment, so we can ensure the recent PBS listings for #neoadjuvant regimens for Stage III melanoma translate into practice and ultimately better patient outcomes.…
The beauty of Napoli only to be outdone by the incredible scientific discussions pushing the frontiers of #neoadjuvant #immunotherapy across #Cancer at INNOVATE, hands down the best meeting of 2024 led by @Liz_htx03 @PAscierto @ProfCUBlankNKI!
Coming up at #ASTRO25: MSK’s Dr. Nancy Lee (@imrtlee) will discuss #neoadjuvant and #adjuvant pembrolizumab plus standard of care in resectable locally advanced head and neck squamous cell #carcinoma. Tuesday, 9/30 | 2:30 p.m. PDT Learn more: bit.ly/4pNSt7K
#ASCO23. NORPACT1 Scandinavian 12-center RCT of upfront surgery vs neoadj FOLFIRINOX for resectable PDAC shows increased toxicity and trend to harm with #neoadjuvant chemo. ➡️Please offer @ALLIANCE_org A021806 to your eligible patients. @FlavioRochaMD
💥DO NOT MISS our Metanalysis on #Perioperative ICI+CT in early #NSCLC • #Neoadjuvant ICI+CT vs CT: ⬆️pCR, MPR, EFS, OS, R0 • ICI+CT ⬆️ pCR in PD-L1 neg • If pCR ➡️ 99% EFS 1 y • Neoadj/periop ICI+CT works better in stage III • Neoadj 🟰 perioperative in OS
Should #neoadjuvant #chemorad only be offered in #PancreaticCancer pts with high CA19.9? Probably not! Joint analysis #PREOPANC 🇳🇱 and #Jang 🇰🇷 multicenter trials: ✅ 127pts low CA19-9 <500: mOS 23.5 vs 16.3 mo (HR 0.63, 0.42 to 0.93) ❌ 52pts high CA19-9 >500: mOS 15.5 vs…
🔥@OncoAlert Hot off the press Merck announces #KEYNOTE671 trial, #Neoadjuvant #Pembrolizumab (vs placebo) + chemo followed by #Adjuvant pembro (vs placebo) in pts with resectable stage II,IIIA or IIIB #NSCLC meets primary endpoint of #OverallSurvival. 👇🏼 merck.com/news/merck-ann…
Latest 🗞️on #neoadjuvant #immunotherapy for advanced, resectable @SquamousCscc #skin #cancer presented last week @myESMO #ESMO2024 showing durable improved survival at 29.4 months 📊#oncsurgery @MDAndersonNews Excited to launch #HN014 @NRGonc @TROGfightcancer 🔜
53 pts accrued in #STRASS2 already. @WinanvanHoudt presenting the trial accrual update at #SSO2023 @TARPSWG semiannual meeting. Together we can face the challenges of #neoadjuvant trials in rare cancers. The #sarcoma community is strong❗️@alegronchi
Our review on #neoadjuvant therapy in #PDAC discussing: -Major Clinical Trials -Holistic Resectability Criteria -Role of Laparoscopy -Value of CA19-9 -Chemotherapy Switch -Vascular Reconstruction -Prehabilitation -Future Developments Full Text ➡️ mdpi.com/2072-6694/15/1…
An infographic presented by the AHNS Basic and Translational Science Service The promise and uncertainties of applying the new neoadjuvant anti-PD1 standard created by KEYNOTE-689 #AHNS #neoadjuvant #immunotherapy #HNSCC
Huge congrats to @DrSapnaPatel @MDAndersonNews & team on acritical study (now in @NEJM!!) that gets us to rethink across disease states the way we conceive of #neoadjuvant #IO. Recall seeing the tremendous presentation at #ESMO23; exciting to see it in print! Go @SWOG!
⬇️#PREOPANC2 abstract is out!! Multicenter RCT #neoadjuvant #pancreaticcancer #alvleesklierkanker
PREOPANC-2 - neoadj FFX vs periop gem-based RT for (borderline) resectable PDAC in 375 patients. 21.9 vs 21.3 months HR 0.87 (0.68-1.12) Resection rate 77% vs 75% More details Sunday ESMO. @MarcBesselink @EileenMOReilly @Gio_Marchegiani @FlavioRochaMD @nigeljamieson @ArndtVogel
Great to be at #SkinCancer2024 in Brisbane with soon-to-be @NRGonc #HN014 collaborators @drsydneychng @DrRahulLadwa @GuptaRuta. #neoadjuvant #immunotherapy @SquamousCscc @AusSSC @sueyom
I just had the exciting opportunity to speak at the @RACSurgeons conference! My colleagues from @MelanomaAus, Alex van Akkooi and David Coker, hosted the session where I shared groundbreaking work on #neoadjuvant #immunotherapy – giving cancer drugs before surgery, which is…
INNOVATE conference Naples - I love this think tank meeting! 2nd yr colleague Paolo Ascierto has hosted small but lively group of clinician researchers, clinical trialists and drug developers discuss an ALL #CANCER #NEOADJUVANT #immunotherapy approach. It is one of my favourite…
The NATIC trial, evaluating #Neoadjuvant anti-PD-1 #Tislelizumab + #Chemotherapy in treatment-naïve stage IB3/IIA2 LACC patients, showed promising #Antitumor efficacy and a tolerable safety profile. #STTT #OpenAccess: doi.org/10.1038/s41392…
🎓This narrative review evaluates how #neoadjuvant #chemotherapy alone or in combination with trans-arterial therapies can downstage unresectable #iCCA, enabling surgical resection and improving outcomes. @EricBernicker @MPishvaian @MarkYarchoan @SyedAAhmad5 @yuanjamesrao
🩺 Neoadjuvant Chemotherapy ± Trans-Arterial Therapies for Downstaging Unresectable Intrahepatic #Cholangiocarcinoma 💡 #Multimodal downstaging strategies 💡 Expanding surgical eligibility in #iCCA 💡 Toward better prognosis through tailored therapy 🔗 [oaepublish.com/articles/2394-…]
![HepatomaRes's tweet image. 🩺 Neoadjuvant Chemotherapy ± Trans-Arterial Therapies for Downstaging Unresectable Intrahepatic #Cholangiocarcinoma
💡 #Multimodal downstaging strategies
💡 Expanding surgical eligibility in #iCCA
💡 Toward better prognosis through tailored therapy
🔗 [oaepublish.com/articles/2394-…]](https://pbs.twimg.com/media/G4eWu_-bUAAHLr6.png)
![HepatomaRes's tweet image. 🩺 Neoadjuvant Chemotherapy ± Trans-Arterial Therapies for Downstaging Unresectable Intrahepatic #Cholangiocarcinoma
💡 #Multimodal downstaging strategies
💡 Expanding surgical eligibility in #iCCA
💡 Toward better prognosis through tailored therapy
🔗 [oaepublish.com/articles/2394-…]](https://pbs.twimg.com/media/G4eWwoDaYAA92Vb.jpg)
![HepatomaRes's tweet image. 🩺 Neoadjuvant Chemotherapy ± Trans-Arterial Therapies for Downstaging Unresectable Intrahepatic #Cholangiocarcinoma
💡 #Multimodal downstaging strategies
💡 Expanding surgical eligibility in #iCCA
💡 Toward better prognosis through tailored therapy
🔗 [oaepublish.com/articles/2394-…]](https://pbs.twimg.com/media/G4eWyMZaQAA2fHT.png)
![HepatomaRes's tweet image. 🩺 Neoadjuvant Chemotherapy ± Trans-Arterial Therapies for Downstaging Unresectable Intrahepatic #Cholangiocarcinoma
💡 #Multimodal downstaging strategies
💡 Expanding surgical eligibility in #iCCA
💡 Toward better prognosis through tailored therapy
🔗 [oaepublish.com/articles/2394-…]](https://pbs.twimg.com/media/G4eWzX0a8AI9jui.png)
Congratulations to @drsydneychng @COBLH @TROGfightcancer for being the first 🇦🇺 site to enroll to #HN014 #C-PRE @NRGonc @NCICancerCtrl @CDNCancerTrials @Regeneron #neoadjuvant #OncSurgery @MDAndersonNews
Please join me and other @MelanomaAus multidisciplinary experts at our specialist hybrid #symposium on Neoadjuvant Treatment, so we can ensure the recent PBS listings for #neoadjuvant regimens for Stage III melanoma translate into practice and ultimately better patient outcomes.…
Join Melanoma Institute Australia for a case-based hybrid #symposium designed to support clinicians navigating the evolving treatment landscape, following recent PBS listings of #neoadjuvant regimens for Stage III melanoma. Through interactive discussion and expert commentary,…
Phase 2-3 ZSAB-neoGOLP trial of #neoadjuvant GOLP regimen for resectable i#CCA with high-risk features for recurrence. A positive interim analysis, but not a standard regimen. Novel approaches are needed. #ESMO25 #ESMOAmbassadors @myESMO
This study identifies #CD8+ nTILs as a strong predictor of event‑free survival in #NSCLC following #neoadjuvant PD‑1 #immunochemotherapy, outperforming radiologic and pathologic responses regardless of PD‑L1 status or #LymphNodeMetastasis. @Penn #STTT: doi.org/10.1038/s41392…
Congratulations to Dr Killian Brown on winning the John Mitchell Crouch #Fellowship for his project on #biomarkers and personalised #neoadjuvant therapy in #rectal #cancer, establishing a #biobank of tissue & liquid biopsies to improve patient outcomes. @SydneyLHD @RACSurgeons
🌟Welcome to submit This Special Issue explores MDT's key role in gastric cancer management, including neoadjuvant therapy, GIST treatment, surgical debates, and AI and big data integration in clinical decision-making. #Multidisciplinary #Neoadjuvant #Model #GIST #IntraAbdominalH
❗With #neoadjuvant and #adjuvant treatment strategies gaining momentum as crucial components in the multimodal management of #MIBC, researchers compared the use of both types of therapies for the disease: buff.ly/JLKazEq
💡Assessing #pathological response to #neoadjuvant therapy in #renal cell carcinoma: a systematic review and #guidelines for sampling and reporting standards from the International Neoadjuvant Kidney Cancer Consortium thelancet.com/journals/lanon… @TheLancetOncol It is a true honor…
Coming up at #ASTRO25: MSK’s Dr. Nancy Lee (@imrtlee) will discuss #neoadjuvant and #adjuvant pembrolizumab plus standard of care in resectable locally advanced head and neck squamous cell #carcinoma. Tuesday, 9/30 | 2:30 p.m. PDT Learn more: bit.ly/4pNSt7K
3/ Toxicity: ≥G3 AEs 67% (FFX) vs 60% (CRT); diarrhea 23% vs 1%. More patients with multiple ≥G3 AEs on FFX. #Neoadjuvant #FOLFIRINOX #GIOnc #MedOnc
Congrats to my mentor @giovann64534267 and my friend & colleague @LucreziaBarc on their work! Big shoutout to all the other colleagues from @SanMartino_Ge who contributed 👏👏👏 esmoopen.com/article/S2059-… 🫁#NSCLC #LungCancer #neoadjuvant #adjuvant #perioperative #immunotherapy
Huge meta-analytic work led by @giovann64534267 exploring the efficacy of neoadjuvant and adjuvant IO in resectable NSCLC in different disease subgroups. Happy to have contributed Link: doi.org/10.1016/j.esmo… @ESMO_Open @myESMO @IASLC @SanMartino_Ge @UniGenova @OncoAlert
Our new paper in @LungCaJournal explores #attrition across #adjuvant, #neoadjuvant, and #perioperative #immunotherapy for resectable #NSCLC. It’s a reminder that outcomes depend not only on efficacy but on finishing the path. lungcancerjournal.info/article/S0169-…
lungcancerjournal.info
Attrition with adjuvant, neoadjuvant, and perioperative immunotherapy-based treatment protocols in...
Immunotherapy (IO) has revolutionized the treatment of resectable non-small cell lung cancer (NSCLC), whether used alone or in combination with traditional chemotherapy. The incorporation of IO into...
Our latest published article in @NatureMedicine |#Neoadjuvant #PD1 & #LAG3 #BispecificAntibody & other #ImmuneCheckpointInhibitor combinations in #Melanoma | Great international collaborative effort with an outstanding group of investigators @MoffittNews nature.com/articles/s4159…
#Diseases_MDPI Share the #Article by Oliver Oey, et al. @uwanews Total #Neoadjuvant #Therapy in Locally Advanced #Rectal #Cancer: Insights from the Western Australian Context mdpi.com/2079-9721/12/1…
💡Assessing #pathological response to #neoadjuvant therapy in #renal cell carcinoma: a systematic review and #guidelines for sampling and reporting standards from the International Neoadjuvant Kidney Cancer Consortium thelancet.com/journals/lanon… @TheLancetOncol It is a true honor…
#Melanoma Great debate starting now #Neoadjuvant Therapy @SocSurgOnc #SSO2024 packed room @CharlotteAriyan Alex Van Akkooi @CureMelanoma @MelanomaReAlli @MelanomaAus @AnnSurgOncol @AIMatMelanoma
Here it is! 🗞️ Presented today @myESMO #ESMO2023 and published concurrently in @TheLancetOncol Favorable survival with #neoadjuvant #immunotherapy in resectable #squamous #skin #cancer #cSCC @SquamousCscc #hncsm @AHNSinfo @Regeneron @MDAndersonNews
I am so proud of leading the #Neoadjuvant NADINA phase 3 clinical trial (with Dutch colleague Prof Blank from @NKI_nl) and with the support of my amazing colleagues at @MelanomaAus. Today, this #immunotherapy regimen (ipilimumab+nivolumab) is listed on PBS for ALL AUSSIES with…
The beauty of Napoli only to be outdone by the incredible scientific discussions pushing the frontiers of #neoadjuvant #immunotherapy across #Cancer at INNOVATE, hands down the best meeting of 2024 led by @Liz_htx03 @PAscierto @ProfCUBlankNKI!
⬇️#PREOPANC2 abstract is out!! Multicenter RCT #neoadjuvant #pancreaticcancer #alvleesklierkanker
PREOPANC-2 - neoadj FFX vs periop gem-based RT for (borderline) resectable PDAC in 375 patients. 21.9 vs 21.3 months HR 0.87 (0.68-1.12) Resection rate 77% vs 75% More details Sunday ESMO. @MarcBesselink @EileenMOReilly @Gio_Marchegiani @FlavioRochaMD @nigeljamieson @ArndtVogel
Amazing keynote lecture by @DrUppaluri @DanaFarber on the potential power of #neoadjuvant #immunotherapy in resectable #headandneckcancer at #hncs24 @ASTRO_org @AHNSinfo @ASCO
Great to be at #SkinCancer2024 in Brisbane with soon-to-be @NRGonc #HN014 collaborators @drsydneychng @DrRahulLadwa @GuptaRuta. #neoadjuvant #immunotherapy @SquamousCscc @AusSSC @sueyom
Exposure to #Neoadjuvant Oxaliplatin-Containing Chemotherapy, Does it Effect #Intraperitoneal #HyperthermicChemotherapy Perfusion? rdcu.be/c7Rqe #VisualAbstract @McMastersKelly
END OF YEAR TOP ALL CANCER TRIALS in 2024! JUST in on 1 JAN 2025: Paper 1: #neoadjuvant checkpoint inhibitor Phase 3 trial in melanoma! #NADINA trial shows ipi+nivo significantly improves EFS vs. adjuvant nivo alone (HR 0.32, p<0.0001). #ASCO24 plenary #Melanoma @ASCO…
Latest 🗞️on #neoadjuvant #immunotherapy for advanced, resectable @SquamousCscc #skin #cancer presented last week @myESMO #ESMO2024 showing durable improved survival at 29.4 months 📊#oncsurgery @MDAndersonNews Excited to launch #HN014 @NRGonc @TROGfightcancer 🔜
Ecstatic and proud to share the NICHE-2 results, now published in @NEJM. Out of 111 pts, 95% had an MPR , and 68% a pCR after only 4 weeks of #neoadjuvant #immunotherapy. Grateful to the pts and colleagues who made this possible. @HaanenJohn nej.md/3Ku4X0H
So proud of our work @NKI_nl @MelanomaAus for #Nadina trial. #neoadjuvant #checkpoint #immunotherapy 68% decrease risk of progression/recurrence & death vs adjuvant anti-pd1. Multidisciplinary teamwork-great for patients with macroscopic stage 3 melanoma. Published today in NEJM…
Teaser #PREOPANC2 design & accrual: Total #Neoadjuvant #FOLFIRINOX in resectable + borderline resect #PancreaticCancer vs “winning arm” #PREOPANC trial #EAHPBA2023: accrual faster than planned ✅, final survival outcome expected in Sept 2023 ✅ @EmmelieDekker @BasGrootKoerkam…
Heading in to #ESMO23 ☀️ 😎 to present updated survival results for the phase 2 trial of #neoadjuvant #immunotherapy in resectable cutaneous #squamous #skin #cancer #cSCC @SquamousCscc @NEJM @AHNSinfo @Regeneron @MDAndersonNews
Should #neoadjuvant #chemorad only be offered in #PancreaticCancer pts with high CA19.9? Probably not! Joint analysis #PREOPANC 🇳🇱 and #Jang 🇰🇷 multicenter trials: ✅ 127pts low CA19-9 <500: mOS 23.5 vs 16.3 mo (HR 0.63, 0.42 to 0.93) ❌ 52pts high CA19-9 >500: mOS 15.5 vs…
Interesting presentation @knutjla Oslo🇳🇴 #EPC2024 highlighting difficulties and differences in #RCTdesign on #neoadjuvant treatment in resectable #PancreaticCancer. 🔑 “These #RCTs actually study a treatment pathway which may include complications of ERCP, EUS etc rather than…
#VisualAbstract : Targeted #AxillaryDissection with 125I Seed Placement Before #Neoadjuvant #Chemotherapy in a Danish Multicenter Cohort rdcu.be/dfWNy
🔥@OncoAlert Hot off the press Merck announces #KEYNOTE671 trial, #Neoadjuvant #Pembrolizumab (vs placebo) + chemo followed by #Adjuvant pembro (vs placebo) in pts with resectable stage II,IIIA or IIIB #NSCLC meets primary endpoint of #OverallSurvival. 👇🏼 merck.com/news/merck-ann…
Inspiring discussion re; #neoadjuvant #melanoma with colleagues from International Neoadjuvant Melanoma Consortium (INMC). Massive positive impact on patient outcomes. Areas to refine - how much surgery is needed, who needs what #immunotherapy & for how long, does #pathology…
Something went wrong.
Something went wrong.
United States Trends
- 1. Veterans Day 165K posts
- 2. Luka 62.8K posts
- 3. Nico Harrison 24.8K posts
- 4. Mavs 21K posts
- 5. #csm220 2,208 posts
- 6. Mainz Biomed N/A
- 7. #MFFL 1,745 posts
- 8. Dumont 15.6K posts
- 9. United States Armed Forces 1,168 posts
- 10. Wike 33.9K posts
- 11. Vets 17.1K posts
- 12. Shams 3,155 posts
- 13. Armistice Day 16K posts
- 14. Centel 1,237 posts
- 15. Made in China 4,239 posts
- 16. Michael Finley N/A
- 17. Mavericks 24.4K posts
- 18. SoftBank 11.5K posts
- 19. #tuesdayvibe 2,405 posts
- 20. Bond 66.4K posts